Second graph of release, the time zones should be CET. (sted, CEST). The corrected release reads: ABSTRACTS HIGHLIGHTING DATA FROM ENZON’S MRNA ANTAGONIST PROGRAMS ACCEPTED FOR PRESENTATION AT 2010 EORTC-NCI-AACR MEETING Novel mRNA Antagonist Compounds Based on Locked Nucleic Acid Technology Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced that data from preclinical studies of three investigational messenger RNA (mRNA) antagonists based on the locked nucleic acid (LNA) technology platform have been accepted for poster presentation at the EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics, which is being held November 16-19 in Berlin, Germany. LNA Compound Poster Presentations “Down-modulation of the androgen receptor with EZN-4176 inhibits the growth of prostate tumor and potentiates the inhibitory effect of MDV-3100, a novel anti-androgen,” Yixian Zhang et al. Poster No. 218, November 17, 12:00 – 2:20 p.m. CET “Down regulation of β-catenin mRNA by a locked nucleic acid oligonucleotide antagonist inhibits tumor growth in experimental models of human cancer,” Melissa Dumble et al. Poster No. 53, November 17, 12:00 – 2:20 p.m. CET “Reduced expression of HER3 with a specific RNA antagonist is associated with antitumor effects in preclinical models of cancer,” Yaming Wu et al. Poster No. 144, November 17, 12:00 – 2:20 p.m. CET “An antisense molecule to HER3 sustains growth inhibitory effects in gefitinib resistant cells that are independent of MET overexpression,” Zhengxing Qu et al. Poster No. 307, November 18, 12:00 – 2:20 p.m. CET About Enzon Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development of innovative medicines for patients with cancer. Enzon's drug development programs utilize several approaches, including its cutting-edge proprietary customized linker-enhanced PEGylation technology and mRNA antagonists using the Locked Nucleic Acid (LNA) technology. Enzon receives a royalty revenue stream from licensing partnerships for other products developed using the proprietary PEGylation technology. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com. Forward Looking Statements There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words "believes," "expects," "may," "will," "should” "potential," "anticipates," "plans," or "intends" and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the timing, success and cost of clinical studies for Enzon's product candidates; the ability to obtain regulatory approval of product candidates, Enzon's ability to obtain the funding necessary to develop its product candidates, market acceptance of, and demand for, Enzon's product candidates and the impact of competitive products, pricing and technology. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2009. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Enzon does not intend to update this information.